Virulence · 2019 · 33 citations · 59 references
Veterinary MedicineImmunologyInfectious DiseasesHost-pathogen InteractionsImmunology Of Infectious DiseasesInnate ImmunityComplement SystemComplement-mediated InjuryInflammation In Infectious DiseaseInnate Immune ResponseInnate Immune Signaling PathwaysSepsis PathophysiologyChemokine ResponsesComplement In Disease PathogenesisComplement In Host DefenseComplement In InfectionComplement In Infectious DiseaseComplement System ActivationComplement-mediated Host DefenseMembrane Attack Complex
The complement system is pivotal in the defense against invasive disease caused by Neisseria meningitidis (Nme, meningococcus), particularly via the membrane attack complex. Complement activation liberates the anaphylatoxins C3a and C5a, which activate three distinct G-protein coupled receptors, C3aR, C5aR1 and C5aR2 (anaphylatoxin receptors, ATRs). We recently discovered that C5aR1 exacerbates the course of the disease, revealing a downside of complement in Nme sepsis. Here, we compared the roles of all three ATRs during mouse nasal colonization, intraperitoneal infection and human whole blood infection with Nme. Deficiency of complement or ATRs did not alter nasal colonization, but significantly affected invasive disease: Compared to WT mice, the disease was aggravated in C3ar−/- mice, whereas C5ar1−/- and C5ar2−/- mice showed increased resistance to meningococcal sepsis. Surprisingly, deletion of either of the ATRs resulted in lower cytokine/chemokine responses, irrespective of the different susceptibilities of the mice. This was similar in ex vivo human whole blood infection using ATR inhibitors. Neutrophil responses to Nme were reduced in C5ar1−/- mouse blood. Upon stimulation with C5a plus Nme, mouse macrophages displayed reduced phosphorylation of ERK1/2, when C5aR1 or C5aR2 were ablated or inhibited, suggesting that both C5a-receptors prime an initial macrophage response to Nme. Finally, in vivo blockade of C5aR1 alone (PMX205) or along with C5aR2 (A8Δ71−73) resulted in ameliorated disease, whereas neither antagonizing C3aR (SB290157) nor its activation with a “super-agonist” peptide (WWGKKYRASKLGLAR) demonstrated a benefit. Thus, C5aR1 and C5aR2 augment disease pathology and are interesting targets for treatment, whereas C3aR is protective in experimental meningococcal sepsis.
59
The chemotactic receptor for human C5a anaphylatoxin
Norma P. Gerard, Craig Gérard · Nature · 1991 · 659 citations
Michael R. Wessels, Peter Butko, Minghe Ma et al. · Proceedings of the National Academy of Sciences · 1995 · 505 citations
Tom Eirik Mollnes, Ole‐Lars Brekke, Michael Fung et al. · PubMed · 2002 · 456 citations